Therapix Biosciences Ltd., a biopharmaceutical company, identifies and develops specialty biopharmaceuticals. It develops LP-306, a novel pharmaceutical based on cannabinoids for pain management; and TRX-318, an oral monoclonal antibody for the treatment of auto-immune and inflammatory diseases. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is based in Tel Aviv, Israel.
5 Azrieli Center (Square Tower)
Tel Aviv, 6702501
Founded in 2004
Therapix Biosciences Signs a Binding Memorandum of Understandings with Yissum
Jul 5 16
Therapix Biosciences has announced that it has entered into a binding memorandum of understandings (MOU) with Yissum to receive an exclusive, worldwide license to use a patent-protected formulation for nasal administration of cannabinoid substances. The technology, developed by Prof. Elka Touitou from the Institute of Drug Research at the Hebrew University of Jerusalem, facilitates administration and effective absorption of the active ingredient THC nasally. The MOU joins the agreement signed last week with a Swiss drug development company to receive a worldwide and exclusive license to use a formulation for sublingual administration of ultralow dosages of THC. Such two agreements form part of the progress in the company's operations in the development and marketing of the formulations for the indications on which the Company has chosen to focus, with an emphasis on treatment of cognitive impairments.
Therapix Biosciences Files Application with the FDA to Approve an Orphan Designation for the Drug
Jun 15 16
Therapix Biosciences announced that it filed an application with the U.S. Food and Drug Administration to approve an orphan drug designation for a drug (THX-RS01) developed based on the entourage technology, which combines cannabinoid substances in treating Tourette syndrome. The application was filed after the completion of the pre-clinical phase and proof-of-concept of the entourage technology and further to the Company's preparations towards the development of a drug based on the technology in the context of clinical trials in humans. The entourage technology is based on the combination of cannabinoid substances or cannabinoid analogs with existing drugs. The technology enables improving the treatment of various medical indications by reducing the standard dosages of the drug, while increasing its efficacy and improving its safety profile.
Therapix Announces Board Appointments
Jun 13 16
Therapix announced that five internationally renowned experts, from Israel and the world, have joined its scientific board and team of consultants. The new experts will join Prof. Raphael Mechoulam, who identified the active compound in cannabis, THC, on the advisory board, and Dr. Yafit Stark, a vice president at Teva and a member of the company's Board of Directors. Such experts will assist the company by providing counsel, planning and executing the clinical trials for which the company is preparing. The experts joining the company include: Prof. James Leckman, a child psychiatrist, psychiatrist and physician at Yale University; Prof. Kirsten Müller-Vahl, Professor of Psychiatry at the Department of Psychiatry, Socialpsychiatry and Psychotherapy of the Hannover Medical School, Germany. Since 1994, she has been serving as a member of the scientific advisory board of the German Tourette-Syndrome Association; Prof. Michael Davidson, Professor of Psychiatry, served as Chief Psychiatrist at the Department of Psychiatry of the Sheba Medical Centre Tel-Hashomer between 2001 and 2007, and currently serves, inter alia, as Chairman of the Stuckinski Centre for Alzheimer'sDisease Research in Ramat Gan; Prof. Avi Weizman, Professor of Psychiatry at the Sackler School of Medicine Tel Aviv University, Head of the Laboratory of Biological Psychiatry at the Felsentein Medical Research Center and Director of the Center and Head of Geha Mental Health Center's Research Unit; and Dr. Michael Bloch, graduated the Yale University School of Medicine and completed his residency in adult and child psychiatry at Yale. Dr. Bloch serves as Chief Resident at Yale's Clinical Neuroscience Research Unit.